• Search chemicals, activators, Inhibitors, APIs, intermediates and raw materials.

1071992-99-8 (AT-406)

1

Identification

AT-406 AT-406
Name AT-406
Formula C32H43N5O4
MW 561.71
CAS No. 1071992-99-8
EINECS
Smiles O=C([[email protected]@H]1CC[[email protected]@](CCN(C(CC(C)C)=O)C[[email protected]@H]2NC([[email protected]@H](NC)C)=O)([H])N1C2=O)NC(C3=CC=CC=C3)C4=CC=CC=C4
Synonyms SM-406;AT406;AT 406;SM406;SM 406; (5S,8S,10aR)-N-benzhydryl-5-((S)-2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo[1,2-a][1,5]diazocine-8-carboxamide
InChI InChI=1S/C32H43N5O4/c1-21(2)19-28(38)36-18-17-25-15-16-27(37(25)32(41)26(20-36)34-30(39)22(3)33-4)31(40)35-29(23-11-7-5-8-12-23)24-13-9-6-10-14-24/h5-14,21-22,25-27,29,33H,15-20H2,1-4H3,(H,34,39)(H,35,40)/t22-,25+,26-,27-/m0/s1
2

Introduction

AT-406(SM-406) is a potent and orally bioavailable Smac mimetic and an antagonist of the inhibitor of apoptosis proteins (IAPs), AT-406 binds to XIAP, cIAP1, and cIAP2 proteins with K(i) of 66.4, 1.9, and 5.1 nM, respectively.

Background Information

AT-406 (formerly known as SM-406) is a novel and orally active antagonist of multiple IAP proteins. AT-406 selectively inhibits the biological activity of IAP proteins, including X chromosome-linked IAP (XIAP), the cellular IAPs 1 (c-IAP1) and 2 (c-IAP2) and melanoma inhibitor of apoptosis protein (ML-IAP). AT-406 effectively antagonizes XIAP BIR3 protein in a cell-free functional assay. AT-406 induced apoptosis is correlated with its ability to down-regulate XIAP whereas AT-406 induces cIAP1 degradation in both AT-406 sensitive and resistance cell lines. AT-406 is highly effective in induction of apoptosis in xenograft tumors, and is capable of complete inhibition of tumor growth. Additionally, AT-406 enhances the carboplatin-induced ovarian cancer cell death and increases survival of the experimental mice in vivo. AT-406 is currently in phase I clinical trials for the treatment of human cancer. ......by AbMole BioScience
AT-406 is an orally bioavailable inhibitor of IAP family of proteins with potential apoptotic inducing and antineoplastic activity. AT-406 selectively inhibits the biological activity of IAP proteins, including X chromosome-linked IAP (XIAP), the cellular IAPs 1 (c-IAP1) and 2 (c-IAP2) and melanoma inhibitor of apoptosis protein (ML-IAP). ......by AdooQ BioScience, LLC
AT406 (SM-406, ARRY-334543) is a potent Smac mimetic and an antagonist of IAP (inhibitor of apoptosis protein via E3 ubiquitin ligase), binding to XIAP-BIR3 (with Ki of 66.4 nM), cIAP1-BIR3(with Ki of 1.9 nM) and cIAP2-BIR3 ( with Ki of 5.1 nM), respectiv ......by BOC Sciences
AT-406 is a potent inhibitor of IAP (inhibitor of apoptosis protein) family of proteins with potential apoptotic inducing and antineoplastic activity. AT-406 selectively inhibits the biological activity of IAP proteins, including X chromosome-linked IAP (XIAP), the cellular IAPs 1 (c-IAP1) and 2 (c-IAP2) and melanoma inhibitor of apoptosis protein (ML-IAP). ......by BioVision, Inc.,
DeBio-1143, also known as AT-406, ARRY-334543and SM-406, is an orally bioavailable inhibitor of IAP (Inhibitor of Apoptosis Protein) family of proteins with potential apoptotic inducing and antineoplastic activity. AT-406 selectively inhibits the biological activity of IAP proteins, including X chromosome-linked IAP (XIAP), the cellular IAPs 1 (c-IAP1) and 2 (c-IAP2) and melanoma inhibitor of apoptosis protein (ML-IAP). This may restore and promote the induction of apoptosis through apoptotic signaling pathways. AT-406 may work synergistically with cytotoxic drugs to overcome tumor cell resistance to apoptosis. ......by MedKoo Biosciences, Inc.
AT406 (SM-406) is a potent Smac mimetic and an antagonist of IAP (inhibitor of apoptosis protein via E3 ubiquitin ligase), binding to XIAP-BIR3, cIAP1-BIR3 and cIAP2-BIR3 with Ki of 66.4 nM, 1.9 nM, and 5.1 nM, 50- to 100-fold higher affinities than the Smac AVPI peptide. Phase 1. ......by Selleck Chemicals LLC
3

Protocol(Only for Reference)

Cell Experiment

Animal Experiment

4

Physical and Chemical Properties

Appearance:White to off-white solid EBNumber:EB000017960

Storage condition

Solubility

5

Mechanism and Indication

Signaling Pathways Apoptosis
Target IAP
Research Area Cancer
Indications Cancer Metastatic breast cancer Acute myelogenous leukemia
6

Clinical Information

Product Name Sponsor & Collaborators Indications Start Date End Date Phase
AT-406 Ascenta Therapeutics Inc Cancer 2010/2/28 2013/8/31 Phase 1 Clinical
AT-406 Debiopharm SA Metastatic breast cancer 2013/4/30 2017/5/31 Phase 1 Clinical
AT-406 Ascenta Therapeutics Inc Acute myelogenous leukemia 2011/2/28 2013/1/1 Phase 1 Clinical
AT-406 - No Development Reported
7

Safety Data of AT-406

8

Spectral Information

9

Suppliers List

10

Related Products

Other Forms of 1071992-99-8

Name CAS No Formula MW
AT-406 (hydrochloride) 1071992-57-8 C32H44ClN5O4 598.18

Recommended Compounds in IAP

Name CAS No Formula MW
SM-164 957135-43-2 C62H84N14O6 1121.42
CUDC-427 1446182-94-0 C29H36N6O4S 564.7
Embelin 550-24-3 C17H26O4 294.39
Birinapant 1260251-31-7 C42H56F2N8O6 806.94
GDC-0152 873652-48-3 C25H34N6O3S 498.64
LCL161 1005342-46-0 C26H33FN4O3S 500.63
UC-112 383392-66-3 C22H24N2O2 348.44
AZD5582 1258392-53-8 C58H78N8O8 1015.29
BV6 1001600-56-1 C70H96N10O8 1205.57
MX69 1005264-47-0 C27H26N2O4S 474.57
IAP-IN-1 1219498-23-3 C17H12F2N2OS 330.35
SM-122 C28H36N4O3 476.61
SM-173 C80H99N16O8 1412.74
SM-123 C27H33N3O4 463.57
ASTX660 1799328-86-1 C30H42FN5O3 539.6845832
GDC-0152 873652-48-3 C25H34N6O3S 498.6409
CUDC-427 1446182-94-0 C29H36N6O4S 564.6989
SM-164 Hydrochloride C62H85ClN14O6 1157.88

Recommended Compounds in Same Indication

Name CAS No Formula MW
AZD1152 722543-31-9 C26H31FN7O6P 587.54
AZD1152-HQPA 722544-51-6 C26H30FN7O3 507.56
Mocetinostat 726169-73-9 C23H20N6O 396.44
Volasertib 755038-65-4 C34H50N8O3 618.81
PU-H71 873436-91-0 C18H21IN6O2S 512.37
Ostarine 841205-47-8 C19H14F3N3O3 389.33
KX2-391 897016-82-9 C26H29N3O3 431.53
MLN4924 905579-51-3 C21H25N5O4S 443.52
MK-0752 471905-41-6 C21H21ClF2O4S 442.9
Cyclophosphamide 50-18-0 C7H15Cl2N2O2P 261.09
Crenolanib 670220-88-9 C26H29N5O2 443.54
Retaspimycin 857402-23-4 C31H45N3O8 587.7
Retaspimycin (Hydrochloride) 857402-63-2 C31H46ClN3O8 624.17
Octreotide (acetate) 79517-01-4 C51H70N10O12S2 1079.29
Litronesib 910634-41-2 C23H37N5O4S2 511.701
LY2603618 911222-45-2 C18H22BrN5O3 436.3
ARRY-520 (R enantiomer) 885060-08-2 C20H22F2N4O2S 420.48
ARRY-520 885060-09-3 C20H22F2N4O2S 420.48
Ganetespib 888216-25-9 C20H20N4O3 364.4
Ixabepilone 219989-84-1 C27H42N2O5S 506.7
11

Route of Synthesis

12

References

13

More Information

AT-406

Tags: buy 1071992-99-8 IC50 | 1071992-99-8 price | 1071992-99-8 cost | 1071992-99-8 solubility | 1071992-99-8 purchase | 1071992-99-8 manufacturer | 1071992-99-8 research buy | 1071992-99-8 order | 1071992-99-8 MSDS | 1071992-99-8 chemical structure | 1071992-99-8 Storage condition | 1071992-99-8 molecular weight | 1071992-99-8 mw | 1071992-99-8 datasheet | 1071992-99-8 supplier | 1071992-99-8 cell line | 1071992-99-8 NMR | 1071992-99-8 MS | 1071992-99-8 IR | 1071992-99-8 solubility | 1071992-99-8 Safe information | 1071992-99-8 Qc and Spectral Information | 1071992-99-8 Clinical Information | 1071992-99-8 Clinical Trial | 1071992-99-8 Route of Synthesis | 1071992-99-8 storage condition | 1071992-99-8 diseases and conditions | 1071992-99-8 flash point | 1071992-99-8 boiling point | 1071992-99-8 melting point | 1071992-99-8 storage condition | 1071992-99-8 brand